Monday, July 13, 2026

Navkar Corp Q3 results: Shares rally 14% as company swings to profit, margins triple

Date:

Navkar Corporation delivered a strong set of numbers for the December quarter, marking a clear turnaround from the year-ago period on the back of robust revenue growth and a sharp improvement in operating performance.

The integrated logistics solutions provider reported a net profit of ₹9.4 crore in Q3, compared with a loss of ₹11.4 crore in the corresponding quarter last year. Revenue for the quarter rose 44% year-on-year to ₹186 crore from ₹130 crore, reflecting improved business traction.

Operating performance strengthened materially, with EBITDA coming in at ₹33.6 crore, sharply higher than ₹7.3 crore a year earlier.

EBITDA margins expanded to 18% from 6% in the year-ago period, underscoring operating leverage and better cost efficiency.

The strong earnings performance was reflected in the stock’s sharp move on Tuesday. Shares of Navkar Corporation were trading at ₹112.97 on the NSE, up nearly 14% following the earnings announcement. The stock touched an intraday high of ₹113.98.

Navkar Corporation provides integrated logistics solutions in India, with operations spanning Container Freight Stations, Private Freight Terminals and Inland Container Depots. The company handles import and export cargo and offers services including warehousing, customs clearance and container train operations, supported by dedicated railway lines for multimodal transport.

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

Punjab and Haryana HC restrains Oberoi Realty from fresh allotments in Gurugram project

The Punjab and Haryana High Court has restrained Oberoi...

Kusumgar IPO allotment to be finalised today. Here’s GMP, how to check status

सार्वजनिक निर्गम को 128.85 गुना की प्रभावशाली समग्र सदस्यता...

Ukraine reels after US Senator Lindsey Graham’s sudden death, fearing a weaker link to Trump

With the death of Republican Senator Lindsey Graham, Ukraine...

Short-term semaglutide disruption unlikely to dent Dr Reddy’s growth plans: Systematix

Dr Reddy's Laboratories' growth outlook from its semaglutide opportunity...